Related by context. All words. (Click for frequent words.) 59 ConclusionThis 58 Shortened telomeres 58 precaution Wiehle 58 Zevalin consolidation 58 Dose escalation 58 clinical pharmacology studies 57 #F FDG PET 57 Framingham Offspring Study 57 meta regression 57 ACOSOG Z# 57 residual confounding 57 HF ACTION 57 malignant mesothelioma Alfacell 57 Meta analyzes 57 vascular endothelial dysfunction 57 biostatistical analysis 57 induced ischemia 57 Cardiorespiratory fitness 57 Multiple logistic regression 57 Robert Motzer MD 57 preoperative evaluation 57 BEXXAR Therapeutic Regimen 57 Dr. Amytis Towfighi neurology 57 number NCT# ClinicalTrials.gov 57 Francesca Bravi 57 MAGE A3 ASCI 57 preoperative intraoperative 57 PLCO 56 STRIDE PD 56 Trigger Relevant Expiry Required 56 Subgroup analyzes 56 poststroke depression 56 dose proportionality 56 riociguat 56 pexelizumab trials 56 MBCT 56 Coronary artery calcification 56 Sleep disordered breathing 56 Dr. Fombonne 56 randomized controlled trials RCTs 56 endocrinologic 56 overnight polysomnography 56 INTERHEART study 56 acute humoral rejection 56 circadian misalignment 56 symptomatic pulmonary embolism 56 nonpharmacologic 56 adenotonsillectomy 56 prospective multicentre 56 CALGB 55 SYNTAX trial 55 prospective observational studies 55 membranous nephritis 55 pathophysiological mechanisms 55 Subgroup analysis 55 Limperopoulos 55 Wisconsin Sleep Cohort 55 Erectile function 55 PLX STROKE targeting 55 Teriflunomide 55 unmeasured confounders 55 Evidence Therapeutic 55 RE LY trial 55 PLCO trial 55 RSD# oral 55 oncologic outcomes 55 blinded randomized placebo controlled 55 pivotal bioequivalence 55 PRIMO CABG 55 symptomatic VTE 55 prospective longitudinal 55 REVIVE Diabetes 55 Elena Losina 55 multivariate logistic regression 55 left ventricular diastolic 55 Diabetes Interventions 55 Coronary CTA 55 Symptom severity 55 postoperative atrial fibrillation 55 Outpatient Setting 55 thorough QT 55 atherogenic dyslipidemia 55 LibiGel Phase III 55 recurrent glioma 55 HER2 expression 55 Carotid Revascularization Endarterectomy vs. 55 Heather Eliassen 55 postoperative mortality 55 BARI 2D 55 BFPET 55 semistructured interviews 55 perioperative complications 55 generalizability 55 K ras mutations 55 genomewide association study 55 Singh Manoux 55 Multivariate logistic regression 55 colonoscopic 55 sedentary postmenopausal 55 elective PCI 54 SIMPADICO 54 Secondary efficacy endpoints 54 prostate carcinogenesis 54 EMPOWER ™ 54 recombinant PSMA vaccine 54 longitudinal cohort study 54 impaired insulin secretion 54 Sudha Seshadri MD 54 Observational studies 54 Randomised controlled trials 54 Tasigna prolongs 54 metaanalysis 54 CPAP adherence 54 unmeasured factors 54 #q# deletion syndrome 54 differential gene expression 54 adjuvant systemic 54 cardiac perfusion imaging 54 immunological responses 54 Jack Pirozzolo 54 ThermoDox ® clinical 54 limiting generalizability 54 blinded randomized controlled 54 prospectively stratified 54 prostate cancer CaP 54 Francine Grodstein 54 pharmacodynamic parameters 54 Timothy Botello 54 SCK difficulty 54 Uncontrolled hypertension 54 periodontal infections 54 kidney urologic 54 conditional logistic regression 54 Michael F. Leitzmann 54 venous thromboembolic disease 54 Professor Najman 54 Angiotensin converting enzyme 54 thromboprophylaxis 54 ACCORD Eye 54 vascular dysfunction 54 chronic myocardial ischemia 54 intracranial stenosis 54 Postoperative complications 54 Randomized trials 54 Edward Giovannucci 54 neuroradiologists 54 HNRCA 54 GERD migraine headaches 54 comorbid disorders 54 ENGAGE AF TIMI 54 radiographic outcomes 54 metabolic parameters 54 Dr. Cookenboo 54 Wactawski Wende 54 cytoreductive nephrectomy 54 ERBITUX infusion 54 MEND CABG 54 Evidence Therapeutic study 54 budesonide MMX Phase III 54 TCF#L# gene 54 cecal intubation 54 statins cholesterol lowering 54 HER2 overexpression 53 Tumor Response 53 Dr. Cassian Yee 53 Confirmatory tests 53 dose escalation phase 53 psychiatric comorbidities 53 Randomized controlled 53 secondary efficacy endpoint 53 Primary endpoints 53 Cochrane reviewers 53 etiologic 53 Dr. Kandzari 53 multicentre prospective 53 spirometric 53 Stacy Tessler Lindau 53 dietary modification 53 Cardiotoxicity 53 electrophysiologic 53 dietary questionnaires 53 See CLINICAL PHARMACOLOGY 53 Kristine Yaffe MD 53 HIV HCV coinfected 53 myocardial ischaemia 53 NATRECOR ® 53 pharmacokinetic characteristics 53 atherogenesis 53 multiple logistic regression 53 Baltimore Longitudinal Study 53 postoperative AF 53 F FDG PET 53 placebo controlled dose escalation 53 Demark Wahnefried 53 multicenter trials 53 renal biopsy 53 subclinical disease 53 antioxidant supplementation 53 intraobserver 53 adenoma recurrence 53 JoAnn Manson 53 Laura Mauri 53 creatinine clearance CrCl 53 testosterone supplementation 53 CURE AF 53 PECARN 53 Screening Trial DMIST 53 erection hardness 53 carotid artery blockage 53 CHD CVD 53 Multivariable logistic regression 53 relapsed MM 53 psoriatic arthritis PsA 53 carotid atherosclerosis 53 Charles Loprinzi MD 53 aortic calcification 53 Virulizin ® 53 intracerebral haemorrhage 53 pharmacodynamic effects 53 VCUG 53 EXPLORE Xa 53 elective percutaneous coronary 53 atherothrombosis 53 Amir Lerman 53 deCODE AF TM 53 echocardiographic parameters 53 EnRhythm MRI SureScan pacing 53 Max Neeman 53 ski lls 53 EMPHASIS HF trial 53 prognostic variables 53 CARDIA 53 Coronary artery bypass grafting 53 randomized Phase 2b 53 prospective observational cohort 53 Coronary angiography 53 genotype phenotype 53 pleiotropic effects 53 endothelin antagonists 53 USPSTF recommends 53 perioperative morbidity 53 Institute DCRI 53 clinicopathological 53 carotid bruit 53 endoscopist 53 Cholesterol Levels SPARCL 53 FFNS 53 Emily Oken 53 EDEMA3 trial 53 Ectopic pregnancy 53 CHAMPION PCI 53 Stenting Trial CREST 53 trastuzumab Herceptin ® 53 pharmacologic stress 53 methodological limitations 53 Lancet Neurology journal 53 CARDIA study 53 Chronic pancreatitis 53 empirically validated 52 PITX2 methylation 52 OPT CHF 52 lipid lowering therapy 52 OnDose TM 52 TIMI Study Group 52 generalisability 52 airway narrowing 52 pharmacologic stress testing 52 pharmacokinetic pharmacodynamic 52 serum leptin 52 IMPACT DCM 52 Reynolds Risk Score 52 Women Ischemia Syndrome 52 Arch Surg 52 APOE genotype 52 HRQL 52 biopsychosocial model 52 thoracoscopic lobectomy 52 diagnostic workup 52 Phase #b/#a 52 hypersensitivity allergic reactions 52 patient centeredness 52 Oncophage vaccination 52 MERLIN TIMI 52 thromboembolic complications 52 pharmacological interventions 52 VITAL Trial 52 coronary CTA 52 methodological weaknesses 52 perinatal morbidity 52 ASPIRE HIGHER 52 Prof. Krainer 52 anesthesia neuroanatomy obstetrics 52 BEXXAR therapeutic regimen 52 creatine supplementation 52 VADT 52 prospectively defined 52 Sociodemographic 52 Goldbeck Wood 52 GI motility disorders 52 aplindore 52 BUSM researchers 52 exploratory endpoints 52 Interrater reliability 52 HYVET 52 potentially modifiable 52 methodologically rigorous 52 hepatic lesions 52 Improper braking 52 cardiac perfusion 52 biopsychosocial 52 pelvic ultrasound 52 Simin Nikbin Meydani 52 predictive validity 52 Rigorous scientific 52 Sherine Gabriel 52 CLBP 52 clinicopathological features 52 RIO Lipids 52 postintervention 52 TACI Ig 52 serum phosphorous 52 Frobell 52 Guillermo Torre Amione 52 thyrotropin levels 52 tumor histology 52 pharmacological therapies 52 genomic alterations 52 tic severity 52 preparticipation 52 aneurysmal subarachnoid hemorrhage 52 obstructive coronary artery 52 Eunyoung Cho 52 Premature menopause 52 NorStates Bank serves 52 Dr. Fehlings 52 serum lipid levels 52 anatomical physiological 52 non fasting triglycerides 52 pharmacodynamics PD 52 C1 INH deficiency 52 Clinical Antipsychotic Trials 52 ICD therapy 52 neuropsychological assessment 52 arterial thickening 52 Dr. Jai Rup 52 serum lipid 52 immunohistochemical 52 EEG abnormalities 52 urinary N telopeptide 52 HORIZONS AMI trial 52 Prostate Lung Colorectal 52 interindividual variability 52 PARTNER Trial 52 Univariate analysis 52 CYT# potent vascular disrupting 52 EGFR mutation status 52 severe hepatic dysfunction 52 journal Resuscitation 52 DMIST 52 Randomized Phase II 52 Netherlands Cohort Study 52 ViaDerm hPTH #-# 52 unmeasured confounding 52 interobserver 52 sonographic examinations 52 journal Ophthalmology 52 NATRECOR R 52 nonfasting triglyceride levels 52 Screening Trial 52 dysbindin gene 52 MADIT II 52 Venous thromboembolism 52 pressure natriuresis 52 colorectal adenoma 52 percutaneous biopsy 52 arterial stiffening 52 Dr. Sudha Seshadri 52 cAMP signaling 52 mg Pycnogenol 52 TAXUS VI 51 chromium supplementation 51 PSMA ADC 51 prospective nonrandomized 51 Towering scholar 51 FGFs 51 polysomnogram 51 autonomic dysfunction 51 PRESEPT 51 proton MR spectroscopy 51 management biostatistical analysis 51 COSIRA trial 51 Dialysis Outcomes 51 website ind.com 51 biologic DMARDs 51 preintervention 51 Trandolapril 51 Erik Ostensoe P. Geo 51 Alternative splicing 51 GVAX Pancreas Vaccine 51 kidney allograft 51 Shlipak 51 coronary arteriography 51 Randomized clinical trials 51 atypical femur fractures 51 histological subtype 51 utmost importance Breithaupt 51 MYTHOS trial 51 journal Gynecologic Oncology 51 BR.# 51 Digital Mammographic Imaging 51 TURBT 51 orofacial clefts 51 colonography 51 transfusion syndrome 51 isoflavone supplement 51 Epidemiologist Renaud Piarroux 51 extrapyramidal symptoms EPS 51 Computational biology 51 SRBD 51 pathologic fractures 51 boards IRBs 51 enzastaurin 51 Professor Hardev Pandha 51 Index CDAI 51 confirmatory clinical 51 androgen depletion 51 Multicenter AIDS 51 submaximal 51 prognostic markers 51 Rasenick 51 EchoCRT 51 fibrinolysis 51 hyperuricaemia 51 randomizing patients 51 intravesical infusion therapy 51 Randomized Double blind 51 dysglycemia 51 coronary catheterization 51 GH deficiency 51 hypobaric hypoxia 51 randomized multicenter trial 51 Sonia Ancoli Israel 51 multivariate Cox 51 System IPSS 51 T1DM 51 cardiac autonomic 51 radiographic findings 51 ongoing Phase IIIb 51 Invasive pneumococcal disease 51 underlying pathophysiology 51 Survivorship Program 51 Gad Getz 51 platelet activation 51 Descriptive statistics 51 Joshua Schier 51 genomic biomarker 51 ER CHOP 51 coronary stenosis 51 macrovascular events 51 Multicenter Automatic Defibrillator Implantation 51 mechanistic studies 51 β blockers 51 antidepressants fluoxetine 51 cerebral microbleeds 51 coinfected patients 51 MET amplification 51 gastrointestinal adverse reactions 51 Hepatotoxicity 51 Marc Legault P.Eng 51 Complications Trial 51 coagulation abnormalities 51 antiangiogenic therapy 51 Refractory Angina 51 antiplatelet medications 51 recurrent VTE 51 neuropsychiatric diseases 51 hip resurfacing arthroplasty 51 Timothy Rebbeck 51 neuropsychological impairments 51 APPROVe trial 51 severe obstructive sleep 51 adjuvant therapies 51 methodologic 51 causal inference 51 Bone density 51 endophenotypes 51 CIMZIA ™ 51 impaired endothelial 51 CARE HF 51 postdischarge 51 molecular determinants 51 AAOS recommends 51 haemodynamic 51 blinded randomized 51 nonrandomized 51 samalizumab 51 hematopoietic cancers 51 Multivariate analysis 51 HIV coinfected 51 allergic airway inflammation 51 androgen excess 51 Blinatumomab 51 neurocognitive functioning 51 PEARL SC 51 androgen suppression 51 DAPT 51 biomarker identification 51 EMPOWER TM 51 arteriography 51 ICD implantation 51 upper endoscopies 51 androgen depletion therapy 51 amyloid cascade 51 acetabular fractures 51 transesophageal echocardiography 51 Multicentre 51 silent ischemia 51 XL# SAR# 51 MediGene focuses 51 HCV SPRINT 51 CSF biomarkers 51 ORAL Solo 51 Skin sterol 51 Enzastaurin 51 subcutaneous PRO 51 Karolinska Institute Stockholm 51 EQUIP OB 51 metabolite concentrations 51 neurology cardiology 51 placebo controlled multicenter 51 Prehypertension 51 myocardial viability 51 LHRH antagonists 51 postoperative chemotherapy 51 J Antimicrob Chemother 51 Cornea Donor Study 51 budesonide foam 51 vestibular rehabilitation 51 somatoform disorders 51 Val HeFT 51 cholinergic tone 51 Gynecologic Oncology Group 51 convergent validity 51 stratifying patients 51 integrative approaches 51 RPGEH 51 trastuzumab emtansine T DM1 51 fusion enhancers 51 Rebecca Garten 51 recurrent miscarriage 51 ALN VSP Phase 51 adrenal suppression 51 carotid artery stenting 51 chest radiographs 51 retrospective cohort 51 perinatal outcomes 51 anthropometric measurements 51 postoperative complication 51 serum GGT 51 TransVax ™ 51 Calcium vitamin D 51 somatic mutations 51 selenium supplementation 51 VTE prevention 51 multicenter randomized clinical 51 antidepressant efficacy 51 Health Initiative Observational 51 chemoprevention trials 50 pharmacodynamic profiles 50 psychopathological symptoms 50 serum estradiol 50 J Immunol 50 journal Psychological Bulletin 50 clefting 50 preclinically 50 hyperalgesia 50 EmbraceAC 50 pulmonary metastasis 50 postoperative pulmonary 50 Tanespimycin 50 allogeneic HSCT 50 beta carotene supplementation 50 Multivariate analyzes 50 angiographically 50 symptomatic DVT 50 GRNCM1 50 prognostic indicators 50 TITLE Auctions 50 dosing cohort 50 Circulatory Physiology 50 Charles Dullin School 50 SE5 OH containing 50 visit http:/www.clinicaltrials.gov/ 50 antitumor efficacy 50 Schaffir 50 sociodemographic factors 50 calcium supplementation 50 bowel resection 50 semistructured interview 50 HDL Selective Delipidation 50 postprocedure 50 Cancer Epidemiol Biomarkers Prev 50 prelicensure 50 skeletal muscle mass 50 Polyp Prevention Trial 50 chorioamnionitis 50 longitudinal observational study 50 topical NSAIDs 50 plasma lipids 50 cardio respiratory endurance 50 familial aggregation 50 RE LY 50 Non inferiority 50 neurodevelopmental outcomes 50 multivariate adjustment 50 STICH trial 50 NNT = 50 Logistic regression 50 familial predisposition 50 variant angina 50 neurocognitive function 50 Richard Suzman Ph.D. 50 Gen. Tito Karnavian 50 genetic loci 50 PRIMO CABG2 50 neurosensory 50 Dr. Zelenetz 50 vitamin B# folic acid 50 renal denervation 50 clinico pathological 50 Dr. Condeelis 50 biochemical abnormalities 50 hawthorn extract 50 journal Arteriosclerosis Thrombosis 50 RTOG 50 pathogenic mechanisms 50 residual platelet reactivity 50 Deforolimus 50 Carotid Stenting 50 nurse navigators 50 prospective observational 50 parasympathetic tone 50 serum biomarkers 50 pharmacodynamic PD 50 pharynx larynx 50 Orthostatic hypotension 50 AMOR IPAT 50 Edge STudy 50 thrombin inhibiting aptamer 50 glycated hemoglobin levels 50 PDE# inhibitors 50 plasma adiponectin 50 Shortlisted candidates 50 STEP BD 50 Lars Sjostrom 50 landmark ATHENA 50 Fibroblast growth 50 antiangiogenic agents 50 TRO# 50 Understanding Universal BCAR 50 immunology genetics 50 causative pathogens 50 psychotherapeutic interventions 50 logistic regression analyzes 50 neurocognitive deficits 50 Normative Aging Study 50 Allergy Cardiovascular 50 pretest probability 50 carotid IMT 50 catheter ablations 50 Subarachnoid hemorrhage 50 antiretroviral naive 50 Prostate Cancer Prevention 50 plasma pharmacokinetics 50 Somnolence 50 visceral adiposity 50 prospective randomized multicenter 50 akinetic mutism 50 interrater reliability 50 cortical activation 50 IMPROVE HF 50 PK PD modeling 50 Myofascial pain 50 aminotransferases 50 noncardiovascular mortality 50 DHEA supplementation 50 histologic subtype 50 Teplizumab 50 IFRD1 50 genotypic resistance 50 observational cohort study 50 empiric therapy 50 asymptomatic hyperuricemia 50 FDG-PET/CT 50 logistic regression models 50 psychoeducational 50 NRF2 gene 50 Insulin PH# 50 CYP#D# genotype 50 multivariable analysis 50 visceral metastases 50 subclinical atherosclerosis 50 preparticipation screening 50 psychosomatic medicine 50 neural degeneration 50 CYP#C# genotype 50 RECORD1 50 Christiane Reitz 50 serum PTH 50 Barbara Sahakian 50 PASI scores 50 Vascugel ® 50 Socioeconomic status 50 pleiotropy 50 longitudinal cohort 50 atherothrombotic disease 50 neurodevelopmental outcome 50 symptomatic hyponatremia 50 Campos Outcalt 50 MGd 50 Deutsches Arzteblatt International 50 Lymph node 50 R#/MEM # 50 bile acid metabolism 50 IBMT 50 Electroencephalography 50 opioid naive 50 postexposure prophylaxis 50 chromosomal imbalance 50 Heavy snorers 50 MMRC clinical trials 50 obstetric ultrasound 50 K ras mutation 50 hemoperfusion 50 APTIVUS r 50 ExCell study 50 NWEA MAP 50 Intervention Trial GAIT 50 antithrombotic therapy 50 pulmonary artery catheterization 50 BMC Neuroscience 50 Pelvic floor 50 AGILECT R 50 plain radiographs 50 immunoregulation 50 radical cystectomy 50 vitro experiments 50 VTEUs 50 Phase III metastatic melanoma 50 BoNTA 50 Dr. Cliby 50 airway responsiveness 50 Prenatal Alcohol 50 extramedullary 50 serum urate levels 50 eculizumab therapy 50 Philip Poi 50 handgrip strength 50 Cochrane Systematic Review 50 Robert Vorona 50 elevated IOP 50 Clinicaltrials.gov 50 HbA1C levels 50 neuropsychological evaluations 50 Zemplar Capsules 50 RCTs 50 weight Wylie Rosett 50 methotrexate therapy 50 airflow limitation 50 androgen deficiency 50 aromatase inhibitor therapy 50 mg BID dose 50 posttreatment 50 recurrent headaches 50 safety tolerability pharmacokinetic 50 Apixaban 50 thromboembolic diseases 50 Aerobic fitness 50 LUMINATE 50 CINQUIL 50 polysomnography PSG 50 preclinical efficacy 50 Stroop task 50 Poisson regression 50 Ovarian PLCO Cancer 50 antiphospholipid antibodies 50 shorter telomere length 50 PROTECT II 50 vitamin D inadequacy 50 clevidipine 50 muscle biopsies 50 multivariable analyzes 50 cardio metabolic diseases 50 Micro RNAs 50 Genetic predisposition 50 Aggressive Reduction 50 Vaxfectin TM 50 Kaplan Meier curve 50 BIIR 50 Febrile neutropenia 50 Corus CAD 50 transrectal ultrasound 50 phase IIb clinical 50 AGHD 50 pharmacologic treatments 50 intima media thickness 50 direct thrombin inhibitors 50 methodological differences 50 Sara Mednick 50 systemic inflammation 50 spatial reasoning 50 Secondhand smoke exposure 50 null responder HCV 50 solithromycin 50 subgroup analyzes 50 Longitudinal studies 50 ovarian hormones 50 Computed Tomographic 50 clopidogrel pretreatment 50 observational cohort 50 FFR measurements 50 cerebral angiography 50 glycemia 50 sociodemographic characteristics 50 randomized crossover 50 tolerability pharmacokinetics 50 premorbid 50 gallstone disease 50 Weese Mayer 50 Tsimikas 49 plasma kallikrein 49 urolithiasis 49 rituximab monotherapy 49 proliferative retinopathy 49 syncopal episode 49 flavopiridol 49 lowering homocysteine levels 49 spinal manipulations 49 VTE prophylaxis 49 Roxana Mehran MD 49 probiotic supplementation 49 inflammatory biomarkers 49 cytologic 49 Paola Sebastiani 49 headaches dizziness disorientation nausea 49 CoQ# supplementation 49 patellofemoral pain syndrome 49 multivariable Cox 49 endoscopic examinations 49 HORIZONS AMI 49 specific CCR9 antagonist 49 menstrual irregularity 49 Rev. Clinton Hagenbach 49 post thrombotic syndrome 49 prognostic significance 49 neuropsychological functioning 49 MIVI TRUST 49 atopic march 49 orthopedics pediatrics 49 R# #mg BID 49 adiponectin levels 49 Acute Decompensated Heart Failure 49 prolonged QT interval 49 university Zanvyl Krieger 49 sonographic examination 49 ERSPC 49 hyperphenylalaninemia HPA due 49 NIHSS score 49 PNH Registry 49 actigraphy 49 CP CPPS 49 hemodilution 49 hepatic arterial 49 arthrography 49 journal Alternative Therapies 49 poststroke 49 Decompensated Heart Failure 49 posaconazole 49 Dr. Scarmeas 49 II Nutrition Cohort 49 Dr. Pasinetti 49 ACRIN 49 untreated OSA 49 toxicologic 49 Vgontzas 49 sorafenib tablets 49 Sleep Disturbances 49 interprofessional education 49 cobas HPV Test 49 SPARCL 49 thrombosis blood clots 49 multiple linear regression 49 ExTRACT TIMI 49 Coronary Artery Bypass Graft 49 PROSTVAC VF 49 dopamine antagonists 49 Oncology Neurosciences Respiratory 49 J Rheumatol 49 CORE OM 49 coexisting illnesses 49 circadian disruption 49 nodal metastases 49 preoperative diagnosis 49 radiofrequency catheter ablation 49 spontaneous regression 49 FDG PET imaging 49 alexithymia 49 corticosteroid dose 49 perfusion MRI 49 endoscopists 49 neuromotor 49 IntroductionThe 49 childhood acute lymphoblastic 49 Oreopoulos 49 metabonomics 49 Phase 1b clinical trials 49 eTag assays 49 cartilage degeneration 49 lipoprotein levels 49 #F FDG PET CT 49 pharmacodynamic markers 49 stone formers 49 multivitamin supplementation 49 MMSE score 49 randomized controlled clinical trials 49 Kathy Giusti myeloma 49 Kidney Int 49 nutrient supplementation 49 liver transplant recipients 49 cardiorespiratory fitness 49 pCR 49 semiquantitative 49 UKPDS 49 anthropometric measures 49 neurologic complications 49 tertiles 49 CALGB # [002] 49 MTWA testing 49 neuroanatomical 49 cortical stimulation 49 CKD MBD 49 carotid artery narrowing 49 intermittent hypoxia 49 LDL HDL 49 didactic lectures 49 noncognitive 49 PROactive study 49 glial tumors 49 Fibromyalgia aquatic 49 CCX# 49 statistically significant correlations 49 Mihai Gheorghiade MD 49 candidate CRLX# 49 myocardial contractility 49 hyperinsulinemic euglycemic clamp 49 liver biopsies 49 CHADS2 49 diagnosing ADHD 49 telomere lengths 49 epigenetic changes 49 ADCS CGIC 49 acetabular dysplasia 49 CardioPET 49 Hilakivi Clarke 49 hypoxemia 49 radiochemotherapy 49 nasopharyngitis headache 49 Buijsse 49 preclinical pharmacokinetic 49 cardiac allograft vasculopathy 49 airway hyperresponsiveness 49 Magnesium deficiency 49 MC4R gene 49 temporomandibular joints 49 Histologic 49 periodically reassessed 49 Lumbar spine 49 Gen. Peter Vangjel 49 tracheal intubation 49 Bresalier 49 Logistic regression analysis 49 dose titration 49 Swedish Mammography Cohort 49 PREVENT IV 49 chlamydial infection 49 multivariate regression analysis 49 abdominal adiposity 49 NAEPP 49 preoperative MRI 49 cardioembolic stroke 49 noncardiac 49 obesity insulin resistance 49 ADVEXIN therapy 49 gynecology paediatrics 49 mg/m2 cohort 49 etiological factors 49 HCV NS5B polymerase 49 journal Pharmacotherapy 49 initiate multicenter